NL-OMON55470已完成不适用
Response measurement study in metastatic castration-resistant prostate cancer patients, treated with radium-223, to improve early response evaluation and understand the radium-223 induced immune response. - Radium223Insight
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Histologically confirmed, progressive prostate cancer during ADT.
- •- Prior treatment with at least two other approved agents for metastatic
- •prostate cancer, unless the patient can*t or doesn*t want to receive other
- •treatments.
- •- Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1.
- •- Life expectancy of 6 months or longer
- •- Adequate hematologic, renal, and liver function.
排除标准
- •- Prior chemotherapy, other than docetaxel.
- •- Previous hemibody external radiotherapy or systemic radiotherapy with
- •radioisotopes within the previous 24 weeks.
- •- A blood transfusion or use of erythropoietin-stimulating agents within the
- •previous 4 weeks
- •- Pathological lymphadenopathy > 1.5 cm in the short-axis diameter on CT or
- •MRI. [68Ga]PSMA positive lymph nodes at baseline are allowed.
- •- A history of presence of visceral metastases on CT or MRI. Patients with
- •[68Ga]PSMA positive lesions that are highly suspected for visceral metastases
- •and are retrospectively visible on CT or MRI should be excluded as well.
- •- Imminent or established spinal cord compression on CT or MRI.
- •- A second active malignancy.
研究者
相似试验
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCEUCTR2021-002641-15-SEPoint BioPharma Inc.390
招募中
3 期
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu- PNT2002 PSMA Therapy After Second-line Hormonal Treatment10027655prostate cancerNL-OMON54469POINT BioPharma,30
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCMetastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002641-15-NLPoint BioPharma Inc.390
撤回
不适用
Evaluation of tumor response during and after (chemo)radiotherapy for patients with oropharyngeal squamous cell carcinoma using functional imaging by diffusion-weighted MRIOropharynx cancerthroat cancer10027655NL-OMON38623Erasmus MC, Universitair Medisch Centrum Rotterdam40
已完成
不适用
Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)Prostatic NeoplasmsNCT02230059Janssen Research & Development, LLC382